



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 94605

TO: Dwayne C Jones
Location: mail 2D01; room 2D07
Art Unit: 1614
Monday, June 02, 2003

Case Serial Number: 038135

From: Barb O'Bryen
Location: Biotech-Chem Library
CM1-6A05
Phone: 308-4291

POB
barbara.obryen@uspto.gov

Search Notes

Dwayne,
The structure of claim 64 is too broad to search.
Claim 69 doesn't make sense. It states "...at least one R of R1, R2, and R3 is substituted or unsubstituted aryl and the R is selected from: mono, di, or tri methyl, methoxy, halo, ..." Since there is no plain "R" in the structure, I interpreted this to mean that whichever of R1, R2, R3 was aryl also had to meet the definitions of "the R". However, most of the things listed in the definition of "the R" are *not* aryls.
I searched only claim 62 and the circled compounds of claims 67 and 70.

Barb

Barbs
only please

94605
SEARCH REQUEST FORM
SEARCHED

Scientific and Technical Information Center

Access DB# _____

Requester's Full Name: Dwayne C. Jones Examiner STC Date: 21 MAY 03
Art Unit: 1614 Phone Number 303-8764 Serial Number: 161038, RS
Mail Box and Bldg/Room Location: 2001, CMA Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched.
Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: See attached sheet

Inventors (please provide full names): 11

Earliest Priority Filing Date: 27 OCT 1999

For Sequence Searches Only* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

20012 6,480,558 (11 of 23) Please search claims 62, 64 and 69
5,592 2 16 of 23 (1)
6,412 64 97/16437 and the circled species of claims 67-70.
9 of 42? 5,475,032 (1) 22-0521 (1)
26 of 42 claim 65-73 (1)
6,235,936 (31 of 41)? list that the variable of
6,423,690?F R is all of R₁, R₂, R₃,
6,231,925 (40 of 41) " However there is no
5,932,698 antecedent basis for the
(12 of 23 = 1?) variable of R. The only variable defined
5,488,116 (5 of 21) in claim 63 are R₁, R₂, R₃
9 of 23 (2) look at 112, 1st WD or 3 enable
so
PTO-1590 (8-01)

STAFF USE ONLY

Searcher: Bob73
Searcher Phone #: _____
Searcher Location: _____
Date Searcher Picked Up: _____
Date Completed: 6-2-03
Searcher Prep & Review Time: _____
Clerical Prep Time: _____
Online Time: _____

Type of Search	Vendors and cost where applicable
NA Sequence (#)	STN _____
AA Sequence (#)	Dialog _____
Structure (#)	Questel/Orbit _____
Bibliographic	Dr. Link _____
Litigation	Lexis/Nexis _____
Fulltext	Sequence Systems _____
Patent Family	WWW/Internet _____
Other	Other (specify) _____

BEST AVAILABLE COPY

L4 1 ANSWERS CAPLUS COPYRIGHT 2003 ACS
IC ICM C12N005-00
ICS C07C213-00
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1, 9
TI Pharmaceutical compositions comprising **primary** N-hydroxylamines
ST hydroxylamine pharmaceutical oxidative damage redn; senescence delay
hydroxylamine pharmaceutical
IT Encephalomyelitis
(autoimmune, hydroxylamines prevention of myelin basic protein-induced,
in rats; pharmaceutical compns. comprising primary N-hydroxylamines)
IT Drug delivery systems
(capsules; pharmaceutical compns. comprising primary N-hydroxylamines)
IT Nitrone
RL: MSC (Miscellaneous)
(compn. free from; pharmaceutical compns. comprising primary
N-hydroxylamines)
IT Aging, animal
Cell aging
(delaying; pharmaceutical compns. comprising primary N-hydroxylamines)
IT Drug screening
(for agents reducing oxidative damage; pharmaceutical compns.
comprising primary N-hydroxylamines)
IT Learning
(hydroxylamines redn. of deficit in, in autoimmune mice; pharmaceutical
compns. comprising primary N-hydroxylamines)
IT Lipopolysaccharides
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(hydroxylamines redn. of inflammation caused by; pharmaceutical compns.
comprising primary N-hydroxylamines)
IT Autoimmune disease
(hydroxylamines redn. of learning deficit in mice with; pharmaceutical
compns. comprising primary N-hydroxylamines)
IT Cytokines
Interleukin 1.beta.
RL: ADV (Adverse effect, including toxicity); BOC (Biological occurrence);
BSU (Biological study, unclassified); BIOL (Biological study); OCCU
(Occurrence)
(hydroxylamines redn. of .beta.-amyloid-induced release of;
pharmaceutical compns. comprising primary N-hydroxylamines)
IT Drug delivery systems
(injections; pharmaceutical compns. comprising primary
N-hydroxylamines)
IT Drug delivery systems
(liqs.; pharmaceutical compns. comprising primary N-hydroxylamines)
IT Behavior
(locomotor, hydroxylamines redn. of A.beta.-amyloid peptide-induced
impairment of, in rats; pharmaceutical compns. comprising primary
N-hydroxylamines)
IT Body weight
(loss, hydroxylamines prevention of myelin basic protein-induced, in
rats; pharmaceutical compns. comprising primary N-hydroxylamines)
IT Drug delivery systems
(lotions; pharmaceutical compns. comprising primary N-hydroxylamines)
IT Nerve
(neuron, hydroxylamines redn. of A.beta.-amyloid peptide
(12-35)-induced loss of, in rats; pharmaceutical compns. comprising
primary N-hydroxylamines)
IT Cytoprotective agents
(neuroprotectants; pharmaceutical compns. comprising primary
N-hydroxylamines)

IT Drug delivery systems
(ointments, creams; pharmaceutical compns. comprising primary N-hydroxylamines)

IT Drug delivery systems
(ointments; pharmaceutical compns. comprising primary N-hydroxylamines)

IT Drug delivery systems
(oral; pharmaceutical compns. comprising primary N-hydroxylamines)

IT Anti-Alzheimer's agents

Anti-inflammatory agents

Anti-ischemic agents

Diagnosis

Drug delivery systems
(pharmaceutical compns. comprising primary N-hydroxylamines)

IT Antioxidants
(pharmaceutical; pharmaceutical compns. comprising primary N-hydroxylamines)

IT Amines, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(primary N-hydroxylamines; pharmaceutical compns. comprising primary N-hydroxylamines)

IT Conformation
(protein, .beta.-pleated sheet, hydroxylamines inhibition of .beta.-amyloid peptide formation of; pharmaceutical compns. comprising primary N-hydroxylamines)

IT Oxidative stress, biological
(redn. of damage from; pharmaceutical compns. comprising primary N-hydroxylamines)

IT Learning
(spatial, disorder, hydroxylamines prevention of N-nitro-L-arginine-caused of, in rats; pharmaceutical compns. comprising primary N-hydroxylamines)

IT Brain, disease
(stroke, treatment of; pharmaceutical compns. comprising primary N-hydroxylamines)

IT Drug delivery systems
(tablets; pharmaceutical compns. comprising primary N-hydroxylamines)

IT Amyloid
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(.beta.-, hydroxylamines inhibition of .beta.-pleated sheet formation by; pharmaceutical compns. comprising primary N-hydroxylamines)

IT Interferons
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(.gamma., hydroxylamines redn. of inflammation caused by; pharmaceutical compns. comprising primary N-hydroxylamines)

IT 541-15-1D, Carnitine, compds.
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compr. further comprising; pharmaceutical compns. comprising primary N-hydroxylamines)

IT 25316-40-9, Adriamycin
RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydroxylamines amelioration of oxidn.-caused side effects of anticancer therapy with; pharmaceutical compns. comprising primary N-hydroxylamines)

IT 3376-24-7, .alpha.-Phenyl-N-tert-butylnitrone
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(pharmaceutical compns. comprising primary N-hydroxylamines)

IT 2211-64-5P, N-Cyclohexylhydroxylamine 5080-22-8P, N-

Isopropylhydroxylamine

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(pharmaceutical compns. comprising primary N-hydroxylamines)

IT 593-77-1, N-Methylhydroxylamine 622-30-0, N-Benzylhydroxylamine
16649-50-6, N-tert-Butylhydroxylamine

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. comprising primary N-hydroxylamines)

IT 64-19-7, Acetic acid, reactions 79-46-9, 2-Nitropropane 25100-12-3,
N-Cyclohexylhydroxylamine hydrochloride

RL: RCT (Reactant); RACT (Reactant or reagent)
(pharmaceutical compns. comprising primary N-hydroxylamines)

IT 621-07-8 622-30-0D, N-(Benzyl)hydroxylamine, derivs. 624-81-7,
N-Ethylhydroxylamine 627-38-3 2912-93-8, N-sec-Butylhydroxylamine
2912-94-9 2912-95-0 2912-97-2 3545-78-6 4410-93-9 4901-28-4
5080-24-0 13782-57-5 14469-03-5 26228-72-8 27886-24-4 29072-73-9